

June 24, 2025

Kidswell Bio Corporation (TSE:4584)

S-Quatre Corporation

PR Release

**Administration Completed in All Three Patients in Clinical Study Using SHED
for the Treatment of Pediatric Cerebral Palsy**

Tokyo, June 24, 2025 - Kidswell Bio Group is engaged in the research and development of novel cell-based therapies (regenerative medicine products) utilizing stem cells from human exfoliated deciduous teeth (SHED), with the aim of developing new treatments for pediatric and rare diseases for which no effective therapies currently exist.

A key milestone has been reached in the clinical study titled “A clinical trial to evaluate the safety and tolerability of stem cells from human exfoliated deciduous teeth in children with cerebral palsy”, led by Nagoya University and jointly conducted with our subsidiary, S-Quatre Corporation, with the completion of administration in all three enrolled pediatric patients.

Safety and efficacy evaluations are currently ongoing for the first and second patients, and an interim analysis including the results from the third patient is scheduled. The results of this interim analysis are expected to be announced by Nagoya University within 2025, marking a significant step toward the next phase.

Our group remains committed-contributing to the future establishment of an effective treatment for cerebral palsy, a refractory disease, based on the results of this clinical study.

Disclaimer: This English translation is provided for reference purposes only. Should any discrepancies arise between this translation and the original Japanese document, the original Japanese document shall take precedence.